# OnCo record nct07468071 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07468071/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07468071", "NCT07468071" ;
  schema:name "Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other"@en ;
  schema:alternateName "KontRASt-R"@en ;
  schema:description "A phase 1/2 trial of JDQ443, Trametinib, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07468071/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07468071> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-06-08" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/tislelizumab/> ;
  onco:companies <https://onco.cc/companies/novartis/> .